Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
TA970: Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments
TA962: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
TA918: Bimekizumab for treating axial spondyloarthritis
TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
TA706: Ozanimod for treating relapsing–remitting multiple sclerosis
TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
TA718: Ixekizumab for treating axial spondyloarthritis
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal)
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
29/07/2020
TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
29/07/2020
TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
29/07/2020
TA340: Ustekinumab for treating active psoriatic arthritis (replaced TA313)
28/07/2020
TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
28/07/2020
TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaced TA376)
28/07/2020
TA315: Canagliflozin in combination therapy for treating type 2 diabetes
28/07/2020
TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
28/07/2020
TA330: Sofosbuvir for treating chronic hepatitis C
28/07/2020
TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaced TA371)
28/07/2020
TA352: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
28/07/2020
TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
28/07/2020
TA336: Empagliflozin in combination therapy for treating type 2 diabetes
24/07/2020
TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
24/07/2020
TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
24/07/2020
TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
24/07/2020
TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA346: Aflibercept for treating diabetic macular oedema
23/07/2020
TA345: Naloxegol for treating opioid‑induced constipation
23/07/2020
TA433: Apremilast for treating active psoriatic arthritis (replaced TA372)
3
4
5
6
7
8
9
10
11
12
13
Follow AWTTC: